TAFAZZIN and atherosclerosis: Our finding that miR-125a-5p downregulates tafazzin in hVSMCs and is induced by oxidised LDL in a NFκB -dependent manner raises the possibility that NFκB -targeted therapies could address both inflammation and mitochondrial dysfunction in atherosclerosis.